Douglas Ward
Directeur Général chez LUMOS DIAGNOSTICS HOLDINGS LIMITED
Fortune : 15 423 $ au 30/04/2024
Postes actifs de Douglas Ward
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Directeur/Membre du Conseil | 13/07/2023 | - |
| Directeur Général | 21/06/2022 | - |
Historique de carrière de Douglas Ward
Anciens postes connus de Douglas Ward
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Personal Genome Diagnostics, Inc.
 Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Directeur Général | 09/05/2016 | 21/04/2020 |
| HOLOGIC, INC. | Corporate Officer/Principal | - | - |
Formation de Douglas Ward
| Ohio Wesleyan University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Australie | 2 |
Opérationnelle
| Chief Executive Officer | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Health Technology |
| HOLOGIC, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Personal Genome Diagnostics, Inc.
Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Health Technology |
- Bourse
- Insiders
- Douglas Ward
- Expérience